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Methylisothiazolinone and methylchloroisothia-
zolinone (MI/MCI) are broad-spectrum preservatives
widely used in cosmetics and household and
industrial products. It is well known that MI/MCI
can cause allergic contact dermatitis with a
spongiotic reaction pattern.1 Because of this
reaction, restrictions have been placed on the
concentration of MI/MCI used in products.2 In recent
years the prevalence of allergic contact dermatitis to
isothiazolinone preservatives, namely, MI/MCI, has
increased dramatically.3 Cosmetic products are some
of the major sources of exposure.
Lichenoid reactions are rare in allergic contact
dermatitis.4 To our knowledge, the occurrence of
lichenoid contact dermatitis to MI/MCI has not been
reported. We report a case of photo-aggravated
lichenoid contact dermatitis in a 63-year-old man
secondary to MI.CASE REPORT
A 63-year-oldmanwith Fitzpatrick skin type 5was
referred for assessment and management of an acute
(4 month) on chronic (3 years) history of a pruritic,
photo-distributed rash in February 2014. The rash
was clinically suggestive of a photo-aggravated
eruption with lichenoid features. Distinctly
violaceous plaques affected the scalp, the lower
third of the forehead, the medial cheeks, the temples
bilaterally (Fig 1) and a fixed erythematous plaque
appeared on the V of the patient’s anterior neck.
Scattered similar plaques were seen on the left
forearm and trunk (the latter more suggestive
of psoriatic plaques). This eruption occurred on aMid-North Coast Area Health Service (NSW)a; The Skin
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40, Australia. E-mail: jwraymond75@gmail.com.background of a 3-year history of a pruritic, scaly,
nonlichenoid-appearing facial eruption that had
been managed with emollients only. Medical
history included plaque psoriasis (managed with
calcipotriol/betamethasone ointment and topical
coal tar/salicyclic acid preparations) and hyperten-
sion managed with a calcium channel blocker
(amlodipine), which was changed to an
angiotensin-converting enzyme inhibitor (perindo-
pril) in mid December 2013. The patient was clear
that the change to perindopril postdated the onset of
the lichenoid rash. Other long-term medications
(metformin and atorvastatin) remained unchanged.
The patient took no other prescription or over-the-
counter medications.
Treatment of the rash before dermatology referral
was with oral prednisone for at least 3 months. The
patient was reluctant to wean the dose beyond 10mg
on alternate days, as his symptoms recurred when
he did. Punch biopsies were taken (while on
prednisone) from the left scalp and right upper
chest, and an autoimmune blood screen was
requested. Histopathology findings were nonspe-
cific, reporting possible lichen simplex chronicus,
drug reaction, or syphilis with the presence of
numerous plasma cells (Fig 2). Importantly,
cutaneous lupus was excluded. Syphilis serology,
antinuclear antibody, extractable nuclear antigen,
and double-stranded DNA were all negative.JAAD Case Reports 2016;2:380-3.
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Fig 1. A and B, Rash at presentation.
Fig 2. A and B, Lichenoid reaction pattern on histopathology.
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patient was weaned off the oral steroids. Control of
the symptoms was achieved with topical betametha-
sone dipropionate, 0.05% daily, to the affected areas
and methylprednisolone aceponate applied daily to
the face until 2 weeks before taking repeat punch
biopsy specimens. Repeat biopsies were performed
given the nonspecific results of the initial biopsies.
These sections were taken from the left sides of the
cheek, jaw line, and forehead and from the right side
of the chest wall. All 3 specimens from the head and
neck showed primarily a spongiotic tissue reaction.
In addition, however, the specimen from the left
cheek showed patchy vacuolar change with occa-
sional apoptotic cells and pigment incontinence,
suggesting a lichenoid reaction pattern consistent
with the clinical pattern seen. Staining for IgG, IgM,
IgA, and fibrinogen were negative. Importantly
again, no evidence of lupus was seen.The topical steroid regime resulted in some
improvement, but the patient continued to have
persistent activity in the head, neck, and trunk
region. The patient was referred for extensive patch
and photo patch testing. Patch testing was
performed (using Chemotechnique IQ-Ultra
chambers) with the department’s baseline series,
preservatives and antimicrobial series, bases of
creams series, perfume series, photo allergens series,
and extra allergens (including the patient’s own
moisturisers and Ionil T shampoo). MI/MCI
100 ppm (Chemotechnique) was used. The patient
was not tested with MI alone, as MI (200 ppm) was
added to our standard series shortly after the testing
of this patient. Test reactions were read at days 2 and
4 according to International Contact Dermatitis
Research Group guidelines. For photo-patch testing,
duplicate allergens were applied to the back and
forearm for 2 days. After removal on day 2, a primary
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irradiated with 5 J/cm2 of ultraviolet A and read
again on day 4. Positive reactions were seen to
p-phenylenediamine 1.0% in petroleum at day 2
(11) and day 4 (/1), N-Isopropyl-N-phenyl-4-
phenylenediamine (IPPD) 0.1% in petroleum at day
2 (11) and day 4 (1), MI and MCI 0.01% in
petroleum day 2 (1) and day 4 (11). No past or
present contact history could be identified to the
IPPD. The patient denied any use of hair dyes or
henna tattoos. The reactions to the p-phenylenedi-
amine and IPPD were considered to represent some
past sensitivity not relevant to the current
presentation.
On further examination of his personal care
products, the patient identified MI on the label
of his bottle of Kenkay Body Wash that he
had been applying predominantly to the head
and neck. E-mail communications with Kenkay
Pharmaceuticals in NSW, Australia, confirmed that
there were 2 formulations for the body wash: (1) the
formulation before August 7, 2013, which contained
MI at a concentration of 0.0095% and (2) the
formulation after August 7, 2013, which includes
piroctone olamine (which replaces MI), benzoyl
peroxide, ethylenediaminetetraacetic acid (EDTA),
and glycerin. The authors did not further test
the product itself. A repeat open application test to
the Kenkay Body Wash was not performed, as
the patient opted for ceasing use of the product
instead.
Ceasing use of this product and continuation of
topical corticosteroid therapy saw significant
improvement of the rash. At 6-month review after
cessation of the Kenkay Dermatological Body Wash,
most of the lichenoid eruption had cleared leaving
only a small very faint asymptomatic persisting patch
of erythema on the left medial cheek that was
managed with 1% hydrocortisone ointment twice a
day. At 9-month follow-up, all the signs and
symptoms had cleared. Importantly, no change was
made to the patient’s medications, and he continued
his perindopril, atorvastatin, and metformin.
DISCUSSION
We present a case of lichenoid contact dermatitis
caused by MI within a wash-off personal care
product. Isothiazolinone preservatives are widely
used in cosmetic and personal care products. The
most frequently found isothiazolinones in these
products are MI/MCI.5 These agents have gained
prominence since the 1980s, causing an epidemic of
allergic contact dermatitis. A 3:1 concentration of
MI/MCI was found to be a strong sensitizer in adults
and children,6 and that combination was graduallyreplaced with sole use of MI, as it was considered
to be a weaker sensitizer. Notwithstanding, the
incidence of allergic contact dermatitis has increased
because the concentration of MI required to achieve
adequate biocidal activity is greater than the
combination of MCI/MI.7 Research finds that the
individuals most at risk are women older than
40 years with facial eczema who use cosmetics.3
Moreover, in those sensitized, most products used
were either leave-on products or wet wipes as
opposed to rinse-off products like shampoos.8
In Europe, MI/MCI use is precluded in leave-on
cosmetic products, but 15 ppm is considered safe in
rinse-off cosmetic products.2 Yazar et al9 identified
no safe level for MI/MCI in rinse-off products.
MI/MCI continues to be used in household and
other consumer products without restriction on
concentration.10
Irritant or allergic contact dermatitis usually
presents as an eczematous process. Lichenoid
contact dermatitis is a rare form of noneczematous
contact dermatitis with clinical features resembling
lichen planus involving potentially skin and/or
mucosal membranes. Lichenoid contact dermatitis
has been reported with color developers, such as
paraphenylenediamine and its derivatives, nickel,
epoxy resins, aminoglycoside antibiotics, and
methacrylic acid esters for industrial use.4
Lichenoid drug eruption is an important consider-
ation to be excluded. Angiotensin-converting
enzyme inhibitors, amlodipine, and beta blockers
are among several reported causes of lichenoid drug
eruptions.1 Clinically, these lesions may mimic
lichenoid contact dermatitis. The histopathology,
however, usually shows prominent vacuolar change,
civatte bodies, melanin incontinence, and inflamma-
tory infiltrate approximating the dermo-epidermal
junction extending up to mid epidermis and dermis.1
In our case, the histopathology findings showed
predominantly spongoisis with some patchy basal
cell vacuolar change, an occasional apoptotic cell,
and some associated pigment incontinence more
consistent with a lichenoid contact reaction pattern
rather than a drug eruption. In addition, the patient’s
skin eruption only began to definitively clear when
use of the Kenkay Body Wash was ceased.
Although MI is reported to cause a flare in
preexisting oral lichen planus,11 there are no
previously reported cases of MI/MCI causing de
novo lichenoid contact dermatitis as far as the
authors are aware at the time of submission.
Pirmez et al12 recently reported 3 confirmed and 27
suspected cases of photoaggravated allergic contact
dermatitis secondary to MI/MCI, but none had any
lichenoid features histologically.
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Raymond, Konya, and Bakis-Petsoglou 383The case presented is notable because it is the first
reported case of a clinically photo-distributed
lichenoid contact dermatitis secondary to exposure
to MI. This case also highlights the importance of
considering MI/MCI as a causative agent for
lichenoid eruptions and adds weight to the argument
for the removal of MI/MCI as a preservative agent
from, at least, all cosmetic products.
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